

EDITORIAL

The Nobel Prize in Physiology or Medicine 2023 was awarded for discoveries concerning base modifications that enabled the development of effective mRNA vaccines against COVID-19

Fukumi Furukawa^{1,2}

¹ Takatsuki Red Cross Hospital, Takatsuki City, Osaka 569-1096, Japan; ffurukawa@takatsuki.jrc.or.jp, h7gygyff@gmail.com

² Department of Forensic Medicine, Wakayama Medical University, Wakayama City, Wakayama 641-0012, Japan

ARTICLE INFO

Received: 28 October 2023

Accepted: 1 December 2023

Available online: 18 February 2024

COPYRIGHT

Copyright © 2024 by author(s).

Trends in Immunotherapy is published by EnPress Publisher, LLC. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

<https://creativecommons.org/licenses/by-nc/4.0/>

The Nobel Prize in Physiology or Medicine 2023 was awarded to two outstanding scientists for their discoveries concerning base modifications that enabled the development of effective mRNA vaccines against COVID-19^[1,2]. They are Dr. Katalin Karikó and Dr. Drew Weissman.

It is very well known that the reason for this award was for the basic research results and discoveries underpinning the development of effective mRNA vaccines against COVID-19, during the pandemic that began in early 2020^[3-5]. When the COVID-19 outbreak began, it was thought that at least two or more years would be required to develop a completely effective conventional vaccine. However, an effective vaccine was developed much sooner than expected. After the outbreak of the COVID-19 pandemic, two base-modified mRNA vaccines, encoding the SARS-CoV-2 surface protein, were developed in record time. Protective effects of around 95% were reported, and vaccines were approved as early as December 2020.

These vaccines have had a large beneficial effect on people. Recently Nishiura and his group reported that the vaccination led to substantial reductions in the numbers of COVID-19 cases and deaths (33% and 67%, respectively)^[6]. The preventive effect will be further amplified during future pandemic waves caused by variants with shared antigenicity^[6]. However, just as any excellent medical treatment has its pros and cons, there are also reports of downsides to this vaccine therapy^[7-9]. In this issue, Ishikawa provided a detailed explanation of inflammatory skin reactions^[10]. The skin is the organ where side effects are most likely to occur and various skin side effects have been reported, including erythema multiforme^[11]. Regarding side effects, it is necessary to accumulate detailed case studies to clarify causal relationships.

Trends in Immunotherapy is a journal that aims to broadly and deeply learn about the pros and cons of treatments, including for cancer, and share this knowledge and experience among us. In 2018, we introduced the Nobel Prize for Dr. Allison and Dr. Honjo^[12]. The

mission of this journal is to be extremely innovative and highly scientific. I hope that future Nobel Prize winners will be selected from the manuscripts in Trends in Immunotherapy.

We would like to thank Editage (www.editage.jp) for English language editing.

Conflict of interest

The author declares no conflict of interest.

References

1. Available online: <https://www.nobelprize.org/prizes/medicine/2023/press-release/> (accessed on 18 October 2023).
2. Available online: <https://www.nobelprize.org/prizes/medicine/2023/summary/> (accessed on 18 October 2023).
3. Karikó K, Buckstein M, Ni H, et al. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. *Immunity*. 2005, 23(2): 165-175. doi: 10.1016/j.immuni.2005.06.008
4. Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability. *Molecular Therapy*. 2008, 16(11): 1833-1840. doi: 10.1038/mt.2008.200
5. Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. *Nucleic Acids Research*. 2010, 38(17): 5884-5892. doi: 10.1093/nar/gkq347
6. Kayano T, Sasanami M, Kobayashi T, et al. Number of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated individuals in Japan. *The Lancet Regional Health - Western Pacific*. 2022, 28: 100571. doi: 10.1016/j.lanwpc.2022.100571
7. Lamprinou M, Sachinidis A, Stamoula E, et al. COVID-19 vaccines adverse events: potential molecular mechanisms. *Immunologic Research*. 2023, 71(3): 356-372. doi: 10.1007/s12026-023-09357-5
8. Ogata AF, Cheng CA, Desjardins M, et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. *Clinical Infectious Diseases*. 2021, 74(4): 715-718. doi: 10.1093/cid/ciab465
9. Ghaderi S, Mohammadi S. Post-COVID-19 vaccination and the brain: A critical analysis of CNS MRI findings. *Trends in Immunotherapy*. 2023, 7(2): 2885. doi: 10.24294/ti.v7.i2.2885
10. Ishikawa O. The pathophysiology and clinical phenotypes of COVID-19 mRNA vaccine-related cutaneous adverse reactions: A narrative review. *Trends in Immunotherapy* [in press].
11. Matsuo A, Nakashima C, Yanagihara S, et al. Two cases of COVID-19 vaccine-related erythema multiforme under the administration of immune checkpoint inhibitors. *Trends in Immunotherapy*. 2023, 7(2): 2683. doi: 10.24294/ti.v7.i2.2683
12. Furukawa F. The Nobel Prize in Physiology or Medicine 2018 was awarded to Cancer Therapy by Inhibition of Negative Immune Regulation. *Trends in Immunotherapy*. 2018, 2(1). doi: 10.24294/ti.v2.i1.1065